Catalent to Acquire Metrics Contract Services for $475 Million to Expand Oral and High-Potent CDMO Capabilities
August 9, 2022
Catalent, Inc. has agreed to acquire Metrics Contract Services (Metrics), a full-service specialty CDMO based in Greenville, North Carolina, from Mayne Pharma Group Limited for $475 million. The deal is expected to close before the end of calendar year 2023, expanding Catalent’s integrated oral solid formulation development, manufacturing, packaging, and highly potent capacity.
- Buyers
- Catalent, Inc., Mayne Pharma Group Limited
- Targets
- Metrics Contract Services
- Sellers
- Mayne Pharma Group Limited
- Industry
- Healthcare Services
- Location
- North Carolina, United States
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
Novo Holdings Acquires Catalent for $16.5 Billion
December 18, 2024
Healthcare Services
Novo Holdings A/S agreed to acquire Catalent, Inc. in an all-cash transaction valued at approximately $16.5 billion ($63.50 per share). The deal was later completed, and Catalent became a private company under Novo Holdings ownership; Novo Nordisk subsequently acquired Catalent’s three fill-finish sites in Italy, Indiana (USA), and Belgium.
-
Pace Life Sciences Acquires Catalent's RTP Small-Molecule Analytical Services Laboratory
September 26, 2024
Healthcare Services
Pace Life Sciences, a PE-backed CDMO, has acquired Catalent’s Center-of-Excellence for Small Molecule Analytical Services located in Research Triangle Park, North Carolina. The acquisition expands Pace Life Sciences’ national analytical testing network (to nine sites) and strengthens its small- and large-molecule analytical capabilities to support biopharma clients; Catalent sold the site as part of its portfolio adjustments.
-
Catalent Acquires Paragon Bioservices for $1.2 Billion
May 20, 2019
Biotechnology
Catalent, Inc. completed the $1.2 billion acquisition of Paragon Bioservices, Inc., a viral vector development and manufacturing partner for gene therapies, expanding Catalent’s biologics and gene therapy capabilities. Paragon’s Baltimore-area facilities and ~380 employees will join Catalent’s global biologics platform, while Catalent secured financing including incremental term loans and a convertible preferred issuance to Leonard Green & Partners to support the transaction.
-
Ardena Acquires Catalent's Somerset, New Jersey Drug Product Facility
October 14, 2024
Pharmaceuticals
Ardena, a GHO Capital-backed CDMO, has signed a definitive agreement to acquire Catalent's FDA-approved drug product manufacturing facility in Somerset, New Jersey. The acquisition — expected to close in early 2025 subject to approvals — expands Ardena's US footprint and downstream capabilities in oral solid dosage manufacturing and bioanalytical services.
-
Catalent Acquires Bettera Brands from Highlander Partners for $1 Billion
August 30, 2021
Food & Beverage
Catalent, Inc. agreed to acquire Bettera Holdings, LLC (Bettera Brands) from Highlander Partners for $1 billion. The acquisition expands Catalent's consumer health and nutraceutical manufacturing capabilities—adding Bettera's gummy, soft chew, and lozenge production capacity and approximately 500 employees across four U.S. facilities.
-
Consortium Acquires Metrics That Matter (MTM)
February 13, 2025
Cybersecurity
Consortium has acquired Metrics That Matter (MTM) to embed MTM’s real‑time cyber risk analytics into a new Next Generation Value‑Added Reseller offering. The deal gives Consortium an analytics engine to quantify cyber risk, prioritize security investments, and deliver continuous risk measurement to enterprise clients.
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.